

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

=>

Uploading 09922066 (patel).str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:59:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3644 TO ITERATE

27.4% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 69261 TO 76499
PROJECTED ANSWERS: 157 TO 717

L2 6 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 09:04:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72911 TO ITERATE

100.0% PROCESSED 72911 ITERATIONS
SEARCH TIME: 00.00.02

278 ANSWERS

L3 278 SEA SSS FUL L1

=> s l3

L4 12 L3

=> d l4 1-12 bib,ab,hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 2003:117823 CAPLUS

DN 138:170243

TI Preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.λ.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-N-methyl-isobutyramide as selective NK1 antagonists

IN Ballard, Theresa Maria; Hoffmann, Torsten; Poli, Sonia Maria; Schnider, Patrick; Sleight, Andrew

PA F. Hoffmann-La Roche AG, Switz.

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

not prior

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011860	A2	20030213	WO 2002-EP8311	20020726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003064983 A1 20030403 US 2002-196795 20020717
 PRAI EP 2001-118412 A 20010731

OS MARPAT 138:170243

AB The title compds. I [R1 = H, F] which may be used for the treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease or for the treatment of disorders including Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis, edema, allergic rhinitis, Crohn's disease, ocular injury, ocular inflammatory diseases, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunol. or psychosomatic disorders, cancer, withdrawal symptoms of addictive drugs from opiates or nicotine, traumatic brain injury or benign prostatic hyperplasia, were prepd. and formulated. E.g., a 8-step synthesis of I [R1 = H] (starting with 2-chloro-5-nitropyridine and thiomorpholine) which showed pKi of 8.9 for the human NK1 receptor, was given.


IT 474026-03-4P 474026-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.λ.6-thiomorpholin-4-yl)-4-(2-Me or 4-fluoro-2-Me substituted)phenyl-pyridin-3-yl]-N-methyl-isobutyramide as selective NK1 antagonists)

RN 474026-03-4 CAPLUS


CN Benzeneacetamide, N-[6-(1,1-dioxido-4-thiomorpholinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 474026-04-5 CAPLUS
 CN Benzeneacetamide, N-[6-(1,1-dioxido-4-thiomorpholinyl)-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **474026-21-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-Me or 4-fluoro-2-Me substituted)phenyl-pyridin-3-yl]-N-methyl-isobutyramide as selective NK1 antagonists)
 RN 474026-21-6 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-thiomorpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:57902 CAPLUS
 DN 138:117662
 TI Use of NK-1 receptor antagonists for the treatment of brain, spinal or
 nerve injury
 IN Hoffmann, Torsten; Nimmo, Alan John; Sleight, Andrew; Vankan, Pierre;
 Vink, Robert
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

not prior

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006016	A2	20030123	WO 2002-EP7323	20020703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003083345	A1	20030501	US 2002-187587	20020702
PRAI EP 2001-116812	A	20010710		
OS	MARPAT 138:117662			
AB	The invention discloses the use of an NK-1 receptor antagonist (Markush included), e.g. N-(3,5-bis-trifluoromethylbenzyl)-N-methyl-6-(4- methylpiperazin-1-yl)-4-o-tolylnicotinamide, optionally in combination with a magnesium salt, for the treatment and/or prevention of brain, spinal or nerve injury. The invention also relates to pharmaceutical compns. comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient, for the treatment and/or prevention of brain, spinal or nerve injury.			
IT	290296-41-2 290296-42-3 290296-43-4 290296-44-5 290296-45-6 290296-46-7 290296-47-8 290296-50-3 290296-51-4 290296-59-2 290296-66-1 290296-67-2 290296-68-3 290296-72-9 290296-73-0 290296-74-1 290296-75-2 290296-84-3 290296-85-4 290296-86-5 290296-87-6 290296-88-7 290296-89-8 290296-90-1 290296-91-2 290296-92-3 290296-93-4 290296-94-5 290296-95-6 290296-96-7 290296-98-9 290296-99-0 290297-00-6 290297-01-7 290297-05-1 290297-18-6 290297-26-6 290297-30-2 290297-57-3 290297-59-5 290297-61-9 290297-62-0 290297-63-1 290297-65-3 290297-66-4 290298-21-4 391674-73-0 391674-74-1 391674-75-2 391674-76-3 391674-77-4 391674-78-5 391674-79-6 391674-80-9 391674-81-0 391674-82-1 391674-83-2 391674-84-3 391674-85-4 391674-86-5			

391674-87-6 391674-89-8 391674-90-1
 391674-91-2 391674-92-3 391674-93-4
 391674-94-5 391674-95-6 391674-97-8
 391674-98-9 391674-99-0 391675-00-6
 391675-01-7 391675-02-8 393508-70-8
 393508-71-9 393508-72-0 393508-73-1
 393508-74-2 393508-75-3 393508-76-4
 393508-77-5 393508-78-6 393508-79-7
 393508-80-0 393508-81-1 393508-82-2
 393508-84-4 393508-91-3 401891-32-5
 401891-33-6 401891-34-7 401891-35-8
 401891-36-9 401891-37-0 401891-38-1
 401891-39-2 401891-40-5 401891-42-7
 401891-43-8 401891-44-9 401891-45-0
 401891-55-2 401891-63-2 401891-67-6
 401891-70-1 401891-87-0 401891-90-5
 401891-91-6 401891-94-9 401892-00-0
 401892-10-2 401892-12-4 401892-24-8
 401892-25-9 401892-29-3 401892-38-4
 401892-63-5 474026-07-8 474026-11-4
 474026-12-5 474026-13-6 488780-92-3
 488780-93-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(NK-1 receptor antagonist for treatment of brain, spinal or nerve injury)


RN 290296-41-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-42-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-43-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 290296-44-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-45-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-46-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 290296-47-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-ethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-50-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-51-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-59-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-66-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-67-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-68-3 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-72-9 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-73-0 CAPLUS
 CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidiny)-4-(2-methylphenyl)-3-

pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 290296-74-1 CAPLUS
CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 290296-75-2 CAPLUS
CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-84-3 CAPLUS
CN 1-Piperazineacetic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 290296-85-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-86-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-87-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-88-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-


4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-92-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-94-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-methylphenyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-96-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-98-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1,2,4-oxadiazol-3-ylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 290296-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1-piperazinyl]-N-methyl-

4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-05-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-18-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-26-6 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-30-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290297-59-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 290297-61-9 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-62-0 CAPLUS
 CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-63-1 CAPLUS
 CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-65-3 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-66-4 CAPLUS
 CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-chlorophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290298-21-4 CAPLUS
 CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-73-0 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-74-1 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 391674-75-2 CAPLUS
 CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-76-3 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-oxido-1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 391674-77-4 CAPLUS
 CN Benzeneacetamide, N-[6-(dimethyloxidoamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 391674-78-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethyloxidoamino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 391674-79-6 CAPLUS
 CN Benzeneacetamide, N-[6-(4-hydroxy-1-oxido-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-80-9 CAPLUS
 CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methyloxidoamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-81-0 CAPLUS
 CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-oxido-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 391674-82-1 CAPLUS
 CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-83-2 CAPLUS
 CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 391674-84-3 CAPLUS
 CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-85-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester, 4-oxide (9CI) (CA INDEX NAME)




RN 391674-86-5 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester,


1-oxide (9CI) (CA INDEX NAME)




RN 391674-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-oxido-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1,1,4-trioxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-90-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-oxido-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-91-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-92-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(1-methyl-1-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 391674-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 391674-98-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(2-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)

yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-
(9CI) (CA INDEX NAME)




RN 391675-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391675-01-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1-oxide (9CI)
(CA INDEX NAME)




RN 391675-02-8 CAPLUS


CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-70-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 393508-71-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(2-hydroxyethyl)amino]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-72-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-hydroxy-1-piperidinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-73-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethoxy)-1-piperidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-74-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 393508-75-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-6-(4-hydroxy-1-piperidinyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 393508-76-4 CAPLUS
 CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-77-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[(2-hydroxyethyl)amino]-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-78-6 CAPLUS
 CN Benzeneacetamide, N-[6-(2,3-dihydro-4H-1,4-oxazin-4-yl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-79-7 CAPLUS
 CN Benzeneacetamide, N-[6-(acetylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 393508-80-0 CAPLUS
 CN Benzeneacetamide, N-[6-(acetymethylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 393508-81-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-
 pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-82-2 CAPLUS
 CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-84-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-91-3 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-32-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxyacetyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-33-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(cyanomethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-34-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-iodo-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-35-8 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-36-9 CAPLUS
 CN 2-Pyridinecarboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 401891-37-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(hydroxymethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-38-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxy(2-hydroxyethyl)amino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-39-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[(hydroxy(2-hydroxyethyl)amino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-40-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-42-7 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-43-8 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-44-9 CAPLUS
 CN Benzeneacetamide, N-[6-(2,5-dioxo-1-pyrrolidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-45-0 CAPLUS
 CN Benzeneacetamide, N-[6-[[bis(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-55-2 CAPLUS
 CN Benzeneacetamide, N-[6-chloro-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-63-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-(5-acetyl-2-thienyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-67-6 CAPLUS
CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1',2',3',6'-tetrahydro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-70-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxymethyl)phenyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-87-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-90-5 CAPLUS
 CN 3-Pyridinecarboxamide, 6-(3-amino-1-propynyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-91-6 CAPLUS
 CN Benzeneacetamide, N-[6-ethynyl-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-94-9 CAPLUS
 CN Benzeneacetamide, N-[6-[3-(hydroxymethyl)-5-isoxazolyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-00-0 CAPLUS
 CN Benzeneacetamide, N-[6-(3-hydroxy-1-propynyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401892-10-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[[2-hydroxyethyl)sulfinyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-12-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[[1-methyl-1H-imidazol-2-yl]thio]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-24-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfinyl)- (9CI) (CA INDEX NAME)




RN 401892-25-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 401892-29-3 CAPLUS
 CN Benzeneacetamide, N-[6-[(3-methoxyphenyl)sulfinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-38-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-hydroxypropoxy)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-63-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 474026-07-8 CAPLUS
 CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 474026-11-4 CAPLUS
 CN Benzeneacetamide, N-[6-(1H-imidazol-1-yl)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 474026-12-5 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]
]-N,2'-dimethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474026-13-6 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-2'-methyl[2,4'-bipyridin]-5-yl]-
N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
NAME)




RN 488780-92-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-
.alpha.,.alpha.-dimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 488780-93-4 CAPLUS

CN Glycine, N-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-
oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl]-N-(methoxycarbonyl)-
(9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 2002:832668 CAPLUS

DN 137:337901

TI Preparation and use of amides as NK-1 receptor antagonists against benign prostatic hyperplasia

IN Buser, Susanne; Ford, Anthony P. D. W.; Hoffmann, Torsten; Lenz, Barbara; Sleight, Andrew John; Vankan, Pierre

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

not prior

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085458	A2	20021031	WO 2002-EP1085	20020202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK , DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003004157	A1	20030102	US 2002-71570	20020208
PRAI EP 2001-109853	A	20010423		

OS MARPAT 137:337901

AB Use of an NK-1 receptor antagonist for the treatment or prevention of benign prostatic hyperplasia (BPH) is claimed. The preferred NK-1 receptor antagonists are compds. of the general formula [I; R = H, alkyl, alkoxy, halo, CF₃; R₁ = H, halo; RR₁ = CH:CHCH:CH; R₂, R₂₁ = H, halo, CF₃, alkyl, alkoxy, cyano; R₂R₂₁ = CH:CHCH:CH, optionally substituted by 1-2 alkyl, halo, alkoxy; R₃ = H, alkyl; R₃R₃C = cycloalkyl; R₄ = H, N(R₅)₂, NR₅(CH₂)nOH, cyclic tertiary amine, etc.; X = CONR₅, (CH₂)pO, NR₅(CH₂)p, etc.; R₅ = H, cycloalkyl, Ph, PhCH₂, alkyl; n = 0-4; p = 1-3]. Preferred compds. are 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)isobutyramide, 3-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]isobutyramide, 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1.1lambda.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methylisobutyramide, and 2-(3,5-bis-trifluoromethylphenyl)-N-[6-(1,1-dioxo-1.1lambda.6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methylisobutyramide. Thus, 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-(6-thiomorpholin-4-yl-4-o-tolylpyridin-3-yl)isobutyramide (prepn. given) oxone were stirred 2 days at room temp. to give 2-(3,5-bis-trifluoromethylphenyl)-N-[6-(1,1-dioxo-1.1lambda.6-thiomorpholin-4-yl)-4-o-tolylpyridin-3-yl]-N-methylisobutyramide. 2-(3,5-Bistrifluoromethylphenyl)-N-methyl-N-methyl-N-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl)isobutyramide at 60 mg/kg/day orally in dogs reduced prostate wt. by 58% after 39 wk.


IT 474026-03-4P 474026-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. and use of amides as NK-1 receptor antagonists against benign prostatic hyperplasia)

RN 474026-03-4 CAPLUS

CN Benzeneacetamide, N-[6-(1,1-dioxido-4-thiomorpholinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 474026-04-5 CAPLUS
CN Benzeneacetamide, N-[6-(1,1-dioxido-4-thiomorpholinyl)-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 290296-41-2 290296-42-3 290296-43-4
290296-44-5 290296-45-6 290296-46-7
290296-47-8 290296-50-3 290296-51-4
290296-59-2 290296-66-1 290296-67-2
290296-68-3 290296-71-8 290296-72-9
290296-73-0 290296-74-1 290296-75-2
290296-86-5 290296-87-6 290296-88-7
290296-89-8 290296-90-1 290296-91-2
290296-92-3 290296-93-4 290296-94-5
290296-95-6 290296-96-7 290296-98-9
290296-99-0 290297-00-6 290297-01-7
290297-06-2 290297-18-6 290297-26-6
290297-30-2 290297-57-3 290297-59-5
290297-61-9 290297-62-0 290297-65-3
290298-21-4 391674-73-0 391674-74-1
391674-75-2 391674-76-3 391674-77-4
391674-79-6 391674-80-9 391674-81-0
391674-82-1 391674-83-2 391674-84-3
391674-85-4 391674-86-5 391674-87-6
391674-89-8 391674-90-1 391674-91-2
391674-92-3 391674-93-4 391674-94-5
391674-95-6 391674-97-8 391674-98-9


391674-99-0 391675-00-6 391675-01-7
 391675-02-8 393508-70-8 393508-71-9
 393508-72-0 393508-73-1 393508-74-2
 393508-75-3 393508-76-4 393508-77-5
 393508-78-6 393508-79-7 393508-80-0
 393508-81-1 393508-82-2 393508-84-4
 393508-91-3 401891-32-5 401891-33-6
 401891-34-7 401891-35-8 401891-36-9
 401891-37-0 401891-38-1 401891-39-2
 401891-40-5 401891-41-6 401891-42-7
 401891-43-8 401891-44-9 401891-45-0
 401891-55-2 401891-63-2 401891-67-6
 401891-70-1 401891-87-0 401891-90-5
 401891-91-6 401891-94-9 401892-00-0
 401892-10-2 401892-12-4 401892-24-8
 401892-25-9 401892-29-3 401892-38-4
 401892-63-5 474026-05-6 474026-06-7
 474026-07-8 474026-08-9 474026-11-4
 474026-12-5 474026-13-6 474026-14-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(prepn. and use of amides as NK-1 receptor antagonists against benign
 prostatic hyperplasia)


RN 290296-41-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-
 4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-42-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-
 chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-43-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 290296-44-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-45-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-46-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 290296-47-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-N-ethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-50-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-51-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-59-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-66-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-67-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-71-8 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-72-9 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-73-0 CAPLUS
 CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 290296-74-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 290296-75-2 CAPLUS
 CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-86-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-87-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-88-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-92-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-94-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-cyanomethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-96-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-(2-hydroxyethoxy)ethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-98-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1,2,4-oxadiazol-3-ylmethyl)-1-piperazinyl]- (9CI)

(CA INDEX NAME)




RN 290296-99-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-
[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1-piperazinyl]-N-methyl-
4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-
formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-
methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-06-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-18-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-26-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-30-2 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290297-59-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 290297-61-9 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 290297-62-0 CAPLUS

CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-65-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290298-21-4 CAPLUS

CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-73-0 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-74-1 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-75-2 CAPLUS

CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-76-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-oxido-1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-77-4 CAPLUS

CN Benzeneacetamide, N-[6-(dimethyloxidoamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-79-6 CAPLUS

CN Benzeneacetamide, N-[6-(4-hydroxy-1-oxido-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-80-9 CAPLUS


CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methyloxidoamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-81-0 CAPLUS


CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-oxido-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391674-82-1 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-83-2 CAPLUS

CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 391674-84-3 CAPLUS


CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-85-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester, 4-oxide (9CI) (CA INDEX NAME)




RN 391674-86-5 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 391674-87-6 CAPLUS
 CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-oxido-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-89-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1,1,4-trioxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-oxido-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-91-2 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-92-3 CAPLUS


CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(1-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-94-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-95-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 391674-97-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 391674-98-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(2-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-99-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)

yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-
(9CI) (CA INDEX NAME)




RN 391675-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391675-01-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1-oxide (9CI)
(CA INDEX NAME)




RN 391675-02-8 CAPLUS

CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-70-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 393508-71-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(2-hydroxyethyl)amino]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-72-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-hydroxy-1-piperidinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-73-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethoxy)-1-piperidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-74-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393508-75-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-6-(4-hydroxy-1-piperidinyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 393508-76-4 CAPLUS
 CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-77-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[(2-hydroxyethyl)amino]-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-78-6 CAPLUS
 CN Benzeneacetamide, N-[6-(2,3-dihydro-4H-1,4-oxazin-4-yl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-79-7 CAPLUS
 CN Benzeneacetamide, N-[6-(acetylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



RN 393508-80-0 CAPLUS
 CN Benzeneacetamide, N-[6-(acetylmethylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 393508-81-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-
 pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 393508-82-2 CAPLUS

CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-84-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-91-3 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-32-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxyacetyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-33-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(cyanomethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-34-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-iodo-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-35-8 CAPLUS
CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-36-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 401891-37-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(hydroxymethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-38-1 CAPLUS
 CN Benzeneacetamide, N-[6-[hydroxy(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-39-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[hydroxy(2-hydroxyethyl)amino]-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-40-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-41-6 CAPLUS
 CN Benzeneacetamide, N-[6-[[(acetyloxy) acetyl] amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 401891-42-7 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl) amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-43-8 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl) methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-44-9 CAPLUS

CN Benzeneacetamide, N-[6-(2,5-dioxo-1-pyrrolidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401891-45-0 CAPLUS

CN Benzeneacetamide, N-[6-[bis(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401891-55-2 CAPLUS


CN Benzeneacetamide, N-[6-chloro-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-63-2 CAPLUS
 CN 3-Pyridinecarboxamide, 6-(5-acetyl-2-thienyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401891-67-6 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1',2',3',6'-tetrahydro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-70-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxymethyl)phenyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-87-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-90-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-(3-amino-1-propynyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-91-6 CAPLUS

CN Benzeneacetamide, N-[6-ethynyl-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-94-9 CAPLUS

CN Benzeneacetamide, N-[6-[3-(hydroxymethyl)-5-isoxazolyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401892-00-0 CAPLUS


CN Benzeneacetamide, N-[6-(3-hydroxy-1-propynyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401892-10-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[[2-hydroxyethyl)sulfinyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-12-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[[1-methyl-1H-imidazol-2-yl)thio]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401892-24-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfinyl)- (9CI) (CA INDEX NAME)




RN 401892-25-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 401892-29-3 CAPLUS

CN Benzeneacetamide, N-[6-[(3-methoxyphenyl)sulfinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401892-38-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-hydroxypropoxy)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-63-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 474026-05-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(1-naphthalenyl)-2-pyridinyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 474026-06-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(1-naphthalenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 474026-07-8 CAPLUS


CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474026-08-9 CAPLUS
 CN Benzeneacetamide, N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 474026-11-4 CAPLUS
 CN Benzeneacetamide, N-[6-(1H-imidazol-1-yl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474026-12-5 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2'-dimethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474026-13-6 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-2'-methyl[2,4'-bipyridin]-5-yl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 474026-14-7 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethyloxidoamino)-3-pyridinyl]-.alpha.,.alpha.-dimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 474026-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and use of amides as NK-1 receptor antagonists against benign prostatic hyperplasia)

RN 474026-21-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-thiomorpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:777873 CAPLUS
 DN 137:294768
 TI Acid-catalyzed carbonylation process for the manufacture of phenylacetic acid derivatives
 IN Hoffmann-Emery, Fabienne; Scalone, Michelangelo; Spurr, Paul
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079134	A1	20021010	WO 2002-EP1271	20020207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002156313	A1	20021024	US 2002-41123	20020108
US 6531597	B2	20030311		
PRAI EP 2001-103284	A	20010213		
EP 2001-127405	A	20011123		

not prior

OS CASREACT 137:294768; MARPAT 137:294768


AB A process for the prepn. of phenylacetic acid derivs. I [R2a-2b = H, halo, alkoxy, CN, COOH, alkoxy carbonyl, alkyl; R3a-3b = H, alkyl, cycloalkyl or taken together (CH2)n; n = 2,3,5] was disclosed. The process involves reacting an aryl Grignard deriv. with a compd. a carbonyl deriv. followed by carbonylating the resulting carbinol in the presence of a strong acid. For instance, acetone was added to the Grignard reagent derived from 3,5-bis(trifluoromethyl)bromobenzene (Et2O, 16-22.degree.) and the resulting carbinol (14.13 g) in CH2Cl2 pumped into a soln. of CH2Cl2/CF3SO3H/H2O/CO at 30 bar at 20.degree.. Aq. work-up produced 14.98 g of 2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropionic acid with 99.0% purity. The carboxylic acid was converted to the acid chloride and then to a therapeutically active morpholine deriv. in another example. The current process produces .alpha.,.alpha.-dialkylated carboxylic acid derivs. with fewer byproducts than prior art methods.

IT **290296-68-3P**, 2-(3,5-Bis(trifluoromethyl)phenyl)-N-[4-[2-methylphenyl]-6-(morpholin-4-yl)pyridin-3-yl]-N-methylisobutyramide
290297-65-3P, 2-(3,5-Bis(trifluoromethyl)phenyl)-N-[4-[2-chlorophenyl]-6-(morpholin-4-yl)pyridin-3-yl]-N-methylisobutyramide
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(acid-catalyzed carbonylation of carbinols to phenylacetic acid derivs.)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290297-65-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-
N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:465794 CAPLUS
 DN 137:37665
 TI Self-emulsifying lipid matrix (SELM) for oral pharmaceuticals
 IN Kuentz, Martin; Roethlisberger, Dieter
 PA F. Hoffman-La Roche A.-G., Switz.
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

not prior

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047663	A1	20020620	WO 2001-EP14437	20011208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002016085	A5	20020624	AU 2002-16085	20011208
US 2002114837	A1	20020822	US 2001-15925	20011210
PRAI EP 2000-127414	A	20001214		
WO 2001-EP14437	W	20011208		


AB A pharmaceutical compn. for oral administration of an active compd. showing a bioavailability of 20% or less comprises (by wt.) 0.01-15% of an active compd. molecularly dissolved in the compn., 30-80% of an edible lipid matrix, and 1-20% of an edible emulsifier, the ratio between the dose wt. of the active compd. and its soly. in the compn. being equal to or greater than 0.6 mL. The high percentage of fat (30-80%) enables to considerably increase the amt. of the drug molecularly dispersed in the dosage form, thus allowing to significantly reduce the no. of unit doses which must be taken daily by patients. For example, 8 g Cremophor RH 40 were dispersed in 70.08 g of cocoa butter, previously warmed to 70-80.degree.. The temp. of the resulting mixt. was then reduced to about 50-60.degree. and 1.4 g of 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-(6-morpholin-4-yl-4-o-tolylpyridin-3-yl) isobutyramide (I) were dissolved together with 0.02 g vanillin. The temp. of the resulting mixt. was further reduced to 40.degree. and 0.5 g aspartame were added. Finally, 20 g of milk powder were added at about 35.degree. (upper limit of the melting interval of cocoa butter). The resulting homogeneous mixt. was then dosed in molds whereby SELM tablets of 5 g each (corresponding to a vol. of about 5 mL) were obtained showing a ratio between the dose wt. of the active compd. and its soly. in the compn. of at least 4.67 mL. The use of SELM compn. enabled an increase of the bioavailability of I up to 22% in beagle dogs.

IT 290296-68-3 290297-26-6 290297-30-2
 341023-51-6 437703-52-1

RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (self-emulsifying lipid matrix for oral drug delivery systems)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-26-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-30-2 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 341023-51-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 437703-52-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, sulfate (1:1) (9CI)
 (CA INDEX NAME)


CM 1

CRN 290296-68-3
 CMF C29 H29 F6 N3 O2



CM 2

CRN 7664-93-9
 CMF H2 O4 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:157739 CAPLUS
 DN 136:216651
 TI Preparation of 4-phenylpyridines as neurokinin-1 receptor antagonists
 IN Godel, Thierry; Hoffmann, Torsten; Schnider, Patrick; Stadler, Heinz
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 108 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

Appl. PCT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016324	A1	20020228	WO 2001-EP8686	20010727
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002012118	A5	20020304	AU 2002-12118	20010727
	EP 1309559	A1	20030514	EP 2001-980219	20010727
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002040040	A1	20020404	US 2001-922066	20010803
	NO 2003000632	A	20030207	NO 2003-632	20030207
PRAI	EP 2000-117003	A	20000808		
	WO 2001-EP8686	W	20010727		

OS MARPAT 136:216651

AB The title compds. [I; R = H, halo; R1 = (C.tplbond.C)mR11, (CR'=CR'')mR11 (wherein R11 = halo, CN, aryl, etc.; R', R'' = H, OH, alkyl, etc.); R2 = H, alkyl, alkoxy, halo, CF3; R3, R31 = H, alkyl or form together with the C atom to which they are attached a cycloalkyl group; R4, R41 = H, halo, CF3, alkyl, alkoxy; R and R2 or R4 and R41 may be together CH=CHCH=CH, optionally substituted by one or two substituents selected from alkyl, halo or alkoxy; X = CONR8, (CH2)pO, (CH2)pNR8, NR8CO, NR8(CH2)p (wherein R8 = H, alkyl); n = 1-2; m = 0-4; p = 1-2] which are antagonists of the Neurokinin 1 (NK-1, substance P) receptor, and therefore useful in the treatment of diseases, related to this receptor, were prepd. and formulated. E.g., a multi-step synthesis of I [R = H; R1 = N(OH)CH2CH2OH; R2 = Me; R3, R31 = Me; R4 = 3-CF3; R41 = 5-CF3; X = NMeCO] which showed pKi of 9.29 in human NK1 receptor assay, was given.


IT 393508-84-4P 401891-34-7P 401891-36-9P
 401891-37-0P 401891-41-6P 401891-47-2P
 401891-48-3P 401891-49-4P 401891-53-0P
 401891-54-1P 401891-55-2P 401891-56-3P
 401891-58-5P 401891-59-6P 401891-60-9P
 401891-63-2P 401891-66-5P 401891-67-6P
 401891-69-8P 401891-78-9P 401891-80-3P
 401891-86-9P 401891-88-1P 401891-91-6P
 401891-97-2P 401891-98-3P 401892-01-1P
 401892-02-2P 401892-09-9P 401892-12-4P
 401892-18-0P 401892-23-7P 401892-28-2P
 401892-36-2P 401892-40-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)


RN 393508-84-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-34-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-iodo-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-36-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 401891-37-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(hydroxymethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-41-6 CAPLUS
 CN Benzeneacetamide, N-[6-[[[(acetyloxy)acetyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-47-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(2-methoxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-48-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-methoxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-49-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-methoxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-53-0 CAPLUS
 CN Benzeneacetamide, N-[6-chloro-4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-54-1 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-iodo-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-55-2 CAPLUS
 CN Benzeneacetamide, N-[6-chloro-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 401891-56-3 CAPLUS
 CN Benzeneacetamide, N-[6-iodo-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 401891-58-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-
 4-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 401891-59-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-6-iodo-N-methyl- (9CI) (CA INDEX NAME)




RN 401891-60-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-4-(4-fluoro-2-methylphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 401891-63-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(5-acetyl-2-thienyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-66-5 CAPLUS
 CN [2,4'-Bipyridine]-1'(2'H)-carboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-3',6'-dihydro-4-(2-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 401891-67-6 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-1',2',3',6'-tetrahydro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401891-69-8 CAPLUS
 CN Benzoic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 401891-78-9 CAPLUS

CN Benzeneacetamide, N-[6-(4-acetyl-2-thienyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)


RN 401891-80-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-86-9 CAPLUS


CN 2,5-Pyridinedicarboxamide, N5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N5-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-88-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-ethynyl-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401891-91-6 CAPLUS
 CN Benzeneacetamide, N-[6-ethynyl-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-97-2 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(phenylethynyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 401891-98-3 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(1Z)-2-phenylethenyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 401892-01-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(hydroxyphenylmethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-02-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1-hydroxyhexyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-09-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[[2-hydroxyethyl]thio]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401892-12-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[[2-hydroxyethyl]thio]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-18-0 CAPLUS
 CN 3-Pyridinecarboxamide, 6-(2-amino-4-thiazolyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-23-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylthio)- (9CI) (CA INDEX NAME)




RN 401892-28-2 CAPLUS

CN Benzeneacetamide, N-[6-[(3-methoxyphenyl)thio]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-36-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,6-dihydro-N-methyl-4-(2-methylphenyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 401892-40-8 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-1,6-dihydro-6-oxo-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



IT 393508-91-3P 401891-32-5P 401891-33-6P
 401891-35-8P 401891-38-1P 401891-39-2P
 401891-40-5P 401891-42-7P 401891-43-8P
 401891-44-9P 401891-45-0P 401891-46-1P
 401891-50-7P 401891-51-8P 401891-52-9P
 401891-57-4P 401891-61-0P 401891-62-1P
 401891-64-3P 401891-65-4P 401891-68-7P
 401891-70-1P 401891-71-2P 401891-72-3P
 401891-73-4P 401891-74-5P 401891-75-6P
 401891-76-7P 401891-77-8P 401891-79-0P
 401891-83-6P 401891-87-0P 401891-89-2P
 401891-90-5P 401891-92-7P 401891-93-8P
 401891-94-9P 401891-95-0P 401891-96-1P
 401891-99-4P 401892-00-0P 401892-03-3P
 401892-04-4P 401892-05-5P 401892-06-6P
 401892-07-7P 401892-08-8P 401892-10-2P
 401892-11-3P 401892-13-5P 401892-14-6P
 401892-15-7P 401892-16-8P 401892-17-9P
 401892-19-1P 401892-20-4P 401892-21-5P
 401892-22-6P 401892-24-8P 401892-25-9P
 401892-26-0P 401892-27-1P 401892-29-3P
 401892-30-6P 401892-31-7P 401892-32-8P
 401892-33-9P 401892-34-0P 401892-35-1P
 401892-37-3P 401892-38-4P 401892-39-5P
 401892-41-9P 401892-42-0P 401892-43-1P
 401892-44-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)

RN 393508-91-3 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



Elected Species.

RN 401891-32-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxyacetyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



Elected Species.


RN 401891-33-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(cyanomethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-35-8 CAPLUS


CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-38-1 CAPLUS
 CN Benzeneacetamide, N-[6-[hydroxy(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-39-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[hydroxy(2-hydroxyethyl)amino]-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-40-5 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(3-oxo-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-42-7 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-43-8 CAPLUS
 CN Benzeneacetamide, N-[6-[(hydroxyacetyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-44-9 CAPLUS
 CN Benzeneacetamide, N-[6-(2,5-dioxo-1-pyrrolidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-45-0 CAPLUS
 CN Benzeneacetamide, N-[6-[bis(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 401891-46-1 CAPLUS
 CN [2,3'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-50-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(2-hydroxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-51-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-hydroxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-52-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-hydroxyphenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-57-4 CAPLUS


CN Benzeneacetamide, N-[6-chloro-4-(4-fluorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-61-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-6-iodo-N-methyl- (9CI) (CA INDEX NAME)




RN 401891-62-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-4-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 401891-64-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[5-(1-hydroxyethyl)-2-thienyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-65-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3,5-dimethyl-4-isoxazolyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-68-7 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1'-(cyclopropylmethyl)-1',2',3',6'-tetrahydro-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-70-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(hydroxymethyl)phenyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-71-2 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl
]-N,3'-dimethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-72-3 CAPLUS
 CN [2,4'-Bipyridine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl
]-4-(2-chlorophenyl)-N,3'-dimethyl- (9CI) (CA INDEX NAME)




RN 401891-73-4 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3'-methyl[2,4'-bipyridin]-5-yl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 401891-74-5 CAPLUS
 CN [2,4'-Bipyridine]-1'(2'H)-carboxylic acid, 5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-3',6'-dihydro-4-(2-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 401891-75-6 CAPLUS
 CN Benzeneacetamide, N-[6-(4-cyanophenyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-76-7 CAPLUS
 CN Benzeneacetamide, N-[6-(4-fluorophenyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-77-8 CAPLUS
 CN Benzeneacetamide, N-[6-(3,4-difluorophenyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-79-0 CAPLUS
 CN Benzeneacetamide, N-[6-[4-(1-hydroxyethyl)-2-thienyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-83-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 401891-87-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-89-2 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(3-methyl-5-isoxazolyl)-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-90-5 CAPLUS
 CN 3-Pyridinecarboxamide, 6-(3-amino-1-propynyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401891-92-7 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-(3-methyl-5-isoxazolyl)-
 4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)




RN 401891-93-8 CAPLUS
 CN Benzeneacetamide, N-[6-(3-ethyl-5-isoxazolyl)-4-(2-methylphenyl)-3-
 pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-94-9 CAPLUS
 CN Benzeneacetamide, N-[6-[3-(hydroxymethyl)-5-isoxazolyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-95-0 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1H-1,2,3-triazol-4-yl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401891-96-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(3-methyl-4-pyridinyl)ethynyl]-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401891-99-4 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(2-phenylethyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-00-0 CAPLUS
 CN Benzeneacetamide, N-[6-(3-hydroxy-1-propynyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401892-03-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1-chlorohexyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-04-4 CAPLUS
 CN 3-Pyridinecarboxamide, 6-benzoyl-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-05-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 401892-06-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[[3-(trifluoromethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 401892-07-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[(2-methyl-1H-imidazol-1-yl)methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN	401892-08-8	CAPLUS
CN	3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)	




RN	401892-10-2	CAPLUS
CN	3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[[[2-hydroxyethyl)sulfinyl]methyl]-N-methyl-4-(2-methylphenyl)-(9CI) (CA INDEX NAME)	




RN 401892-11-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[[[2-


hydroxyethyl)sulfonylmethyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA
INDEX NAME)




RN 401892-13-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[[[1-methyl-1H-imidazol-2-yl)sulfinyl]methyl]-4-(2-methylphenyl)- (9CI)
(CA INDEX NAME)



RN 401892-14-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[3-(4-methoxyphenyl)propyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-15-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4,4-dimethylpentyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-16-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-cyanopropyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-17-9 CAPLUS

CN Benzeneacetamide, N-[6-acetyl-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-19-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 401892-20-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 401892-21-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 401892-22-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 401892-24-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfinyl)- (9CI) (CA INDEX NAME)




RN 401892-25-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(2-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 401892-26-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]- (9CI) (CA INDEX NAME)




RN 401892-27-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(4-methoxyphenyl)thio]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401892-29-3 CAPLUS
 CN Benzeneacetamide, N-[6-[(3-methoxyphenyl)sulfinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




RN 401892-30-6 CAPLUS
 CN Acetic acid, [[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 401892-31-7 CAPLUS
 CN Propanoic acid, 3-[[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 401892-32-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-cyanophenoxy)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-33-9 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(1H-1,2,4-triazol-1-yl)phenoxy]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-34-0 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-35-1 CAPLUS
 CN Benzeneacetamide, N-[6-(4-cyanophenoxy)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-37-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 401892-38-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(3-hydroxypropoxy)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-39-5 CAPLUS
 CN Benzeneacetamide, N-[1,6-dihydro-4-(2-methylphenyl)-6-oxo-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-41-9 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-methoxy-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-42-0 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-pyridinylmethoxy)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 401892-43-1 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(3-pyridinylmethoxy)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



RN 401892-44-2 CAPLUS
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(phenylmethoxy)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 290296-68-3P 290296-83-2P 290296-89-8P
 290296-93-4P 290297-13-1P 290297-14-2P
 290297-41-5P 391674-73-0P 391674-74-1P
 393508-76-4P 401892-45-3P 401892-46-4P
 401892-56-6P 401892-57-7P 401892-58-8P
 401892-59-9P 401892-60-2P 401892-61-3P
 401892-62-4P 401892-63-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-83-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290296-89-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 290297-13-1 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylmethyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-14-2 CAPLUS
 CN Benzeneacetamide, N-[6-amino-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-41-5 CAPLUS

CN Carbamic acid, [5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 391674-73-0 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-74-1 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-76-4 CAPLUS

CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 401892-45-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(bromoacetyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-46-4 CAPLUS

CN 2-Pyridineacetic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-.alpha.-cyano-4-(2-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401892-56-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)




RN 401892-57-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-propynyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-58-8 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(trimethylsilyl)ethynyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-59-9 CAPLUS

CN Benzeneacetamide, N-[6-[[3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-1-propynyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401892-60-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(hydroxy-4-pyridinylmethyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 401892-61-3 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1-ethoxyethenyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401892-62-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(bromoacetyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 401892-63-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:90050 CAPLUS
 DN 136:134681
 TI Preparation of 4-phenylpyridine derivatives as neurokinin-1 receptor antagonists
 IN Hoffmann, Torsten; Schnider, Patrick; Stadler, Heinz
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

not prior!


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008232	A1	20020131	WO 2001-EP8432	20010720
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002038030	A1	20020328	US 2001-901311	20010709
EP 1305319	A1	20030502	EP 2001-960529	20010720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003000353	A	20030123	NO 2003-353	20030123
PRAI EP 2000-115846	A	20000724		
WO 2001-EP8432	W	20010720		
OS MARPAT 136:134681				
AB The title compds. [I or II; R1 = III, 2,3-dihydro-[1,4]oxazin-4-yl, imidazol-1-yl, [1,2,4]triazol-1-yl, NH(CH ₂) ₂ OH, NR ₃ COCH ₃ , NR ₃ COcyclopropyl; R2 = Me, Cl; R3 = H, Me; R = H, (CH ₂) ₂ OH; n = 1-2] which have a good affinity of the NK-1 receptor and therefore they may be used in the treatment or prevention of diseases, related to this receptor, were prepd. and formulated. E.g., a multi-step synthesis of I [R1 = [1,2,4]triazol-1-yl; R2 = Me] which showed pK _i of 8.4 against binding at human NK1 receptors in CHO cells, was given.				
IT 393508-72-0P 393508-79-7P 393508-81-1P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)				
RN 393508-72-0 CAPLUS				
CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-hydroxy-1-piperidinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)				



RN 393508-79-7 CAPLUS
 CN Benzeneacetamide, N-[6-(acetylamino)-4-(2-methylphenyl)-3-pyridinyl]-
 N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



RN 393508-81-1 CAPLUS
 CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)amino]-4-(2-methylphenyl)-3-
 pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
 (CA INDEX NAME)




IT 393508-70-8P 393508-71-9P 393508-73-1P
 393508-74-2P 393508-75-3P 393508-76-4P
 393508-77-5P 393508-78-6P 393508-80-0P
 393508-82-2P 393508-83-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)

RN 393508-70-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-
 4-(2-methylphenyl)-6-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)




RN 393508-71-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(2-hydroxyethyl)amino]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-73-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethoxy)-1-piperidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 393508-74-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393508-75-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-6-(4-hydroxy-1-piperidinyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 393508-76-4 CAPLUS

CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-77-5 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[(2-hydroxyethyl)amino]-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-78-6 CAPLUS

CN Benzeneacetamide, N-[6-(2,3-dihydro-4H-1,4-oxazin-4-yl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 393508-80-0 CAPLUS

CN Benzeneacetamide, N-[6-(acetylmethylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 393508-82-2 CAPLUS

CN Benzeneacetamide, N-[6-[(cyclopropylcarbonyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 393508-83-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1H-pyrazol-1-yl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 290296-68-3P 290297-13-1P 290297-14-2P

290297-41-5P 393508-84-4P 393508-85-5P

393508-90-2P 393508-91-3P 393508-92-4P


393509-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-13-1 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylmethyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-14-2 CAPLUS
 CN Benzeneacetamide, N-[6-amino-4-(2-methylphenyl)-3-pyridinyl]-
 N',.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
 NAME)



RN 290297-41-5 CAPLUS
 CN Carbamic acid, [5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-
 oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl] (phenylmethyl)-,
 phenylmethyl ester (9CI) (CA INDEX NAME)




RN 393508-84-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-
 N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-85-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-
[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-1-piperidinyl]-N-methyl-4-
(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 393508-90-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-
chlorophenyl)-6-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-1-piperidinyl]-
N-methyl- (9CI) (CA INDEX NAME)




RN 393508-91-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(3-
oxo-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX
NAME)




RN 393508-92-4 CAPLUS

CN Benzeneacetamide, N-[6-(3-hydroxy-4-morpholinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 393509-29-0 CAPLUS

CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(1H-pyrazol-1-yl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 2002:72051 CAPLUS

DN 136:118387

TI Preparation of N-oxides as NK1 receptor antagonist prodrugs of 4-phenylpyridine derivatives

IN Hoffmann, Torsten; Poli, Sonia Maria; Schnider, Patrick; Sleight, Andrew

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

not prior!

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002006236	A1	20020124	WO 2001-EP7850	20010709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1303490	A1	20030423	EP 2001-949475	20010709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002045642	A1	20020418	US 2001-904059	20010712
NO 2003000154	A	20030113	NO 2003-154	20030113
PRAI EP 2000-115287	A	20000714		
WO 2001-EP7850	W	20010709		

OS MARPAT 136:118387

AB The prepn. is described for N-oxides (I) wherein R is hydrogen, lower alkyl, lower alkoxy, or trifluoromethyl; R1 is hydrogen or halogen; or R and R1 may be together with the ring carbon atoms to which they are attached -CH=CH-CH=CH-; R2 and R2' are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R2 and R2' may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R3, R3' are independently from each other hydrogen, lower alkyl or cycloalkyl; R4, R4' are independently from each other -(CH2)mOR6 or lower alkyl; or R4 and R4' form together with the N-atom to which they are attached a cyclic tertiary amine with substituent R5 chosen from hydrogen, hydroxy, lower alkyl, -lower alkoxy, -(CH2)mOH, -COOR3, -CON(R3)2, -N(R3)CO-lower alkyl or -C(O)R3; R6 is hydrogen, lower alkyl or phenyl; X is -C(O)N(R6)-, -N(R6)C(O)-, -(CH2)mO- or -O(CH2)m-; n is 0, 1, 2, 3 or 4 and; m is 1, 2, or 3; and to their pharmaceutically acceptable acid addn. salts. These compds. may be used as prodrugs for the treatment or prevention of illnesses, related to the NK1 receptor. Thus, 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(4-oxymorpholin-4-yl)-4-o-tolylpyridin-3-yl]isobutyramide (II) and related compds. were prepd. in multistep procedures.

IT 290296-68-3P 290296-70-7P 290296-71-8P
 290296-73-0P 290296-74-1P 290296-75-2P
 290296-76-3P 290296-77-4P 290296-83-2P
 290296-85-4P 290296-87-6P 290296-89-8P
 290296-90-1P 290296-91-2P 290296-92-3P
 290297-00-6P 290297-01-7P 290297-02-8P

290297-03-9P 290297-04-0P 290297-05-1P

290297-06-2P 290297-07-3P 290297-08-4P

290297-10-8P 290297-11-9P 290298-21-4P


391675-02-8P 391675-03-9P 391675-11-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate product in prepn. of aminopyridine N-oxides as NK1
receptor antagonist prodrugs of 4-phenylpyridine derivs.)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-70-7 CAPLUS

CN Benzeneacetamide, N-[6-(dimethylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-71-8 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-73-0 CAPLUS


CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 290296-74-1 CAPLUS


CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 290296-75-2 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-76-3 CAPLUS

CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290296-77-4 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-83-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290296-85-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-87-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-92-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-02-8 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-03-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-04-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-05-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-06-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-07-3 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 290297-08-4 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-10-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-11-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290298-21-4 CAPLUS

CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391675-02-8 CAPLUS


CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391675-03-9 CAPLUS


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

NAME)



RN 391675-11-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1-tetrazolidinyl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 391674-73-0P 391674-74-1P 391674-75-2P
 391674-76-3P 391674-77-4P 391674-78-5P
 391674-79-6P 391674-80-9P 391674-81-0P
 391674-82-1P 391674-83-2P 391674-84-3P
 391674-85-4P 391674-86-5P 391674-87-6P
 391674-88-7P 391674-89-8P 391674-90-1P
 391674-91-2P 391674-92-3P 391674-93-4P
 391674-94-5P 391674-95-6P 391674-96-7P
 391674-97-8P 391674-98-9P 391674-99-0P
 391675-00-6P 391675-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminopyridine N-oxides as NK1 receptor antagonist prodrugs of 4-phenylpyridine derivs.)


RN 391674-73-0 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-74-1 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-75-2 CAPLUS

CN Benzeneacetamide, .alpha.,.alpha.-dimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-76-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-oxido-1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-77-4 CAPLUS

CN Benzeneacetamide, N-[6-(dimethyloxidoamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-78-5 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethyloxidoamino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 391674-79-6 CAPLUS

CN Benzeneacetamide, N-[6-(4-hydroxy-1-oxido-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-80-9 CAPLUS


CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methyloxidoamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-81-0 CAPLUS


CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-oxido-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391674-82-1 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 391674-83-2 CAPLUS

CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 391674-84-3 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 391674-85-4 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl-, 1,1-dimethylethyl ester, 4-oxide (9CI) (CA INDEX NAME)



RN 391674-86-5 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl-, ethyl ester, (9CI) (CA INDEX NAME)

1-oxide (9CI) (CA INDEX NAME)




RN 391674-87-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-oxido-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-88-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 391674-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1,1,4-trioxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-oxido-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 391674-91-2 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-92-3 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(1-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-94-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-96-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-97-8 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 391674-98-9 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-N-(2-naphthalenylmethyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391674-99-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 391675-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 391675-01-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1-oxide (9CI) (CA INDEX NAME)


IT **290296-93-4**

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant for prepn. of aminopyridine N-oxides as NK1 receptor antagonist prodrugs of 4-phenylpyridine derivs.)

RN 290296-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:396485 CAPLUS
 DN 135:5533
 TI Process for preparation of pyridine derivatives
 IN Hilpert, Hans; Hoffmann-Emery, Fabienne; Rimmeler, Goesta; Rogers-Evans, Mark; Stahr, Helmut Werner; Waldmeier, Pius
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1103546	A1	20010530	EP 2000-125665	20001123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
→	US 6303790	B1	20011016	US 2000-716538	20001120 ←
	JP 2001151755	A2	20010605	JP 2000-360682	20001128
	JP 3403164	B2	20030506		
	CN 1297887	A	20010606	CN 2000-128383	20001128
PRAI	EP 1999-123686	A	19991129		

*claims drawn to process!
(no DP)*

OS CASREACT 135:5533; MARPAT 135:5533


AB The title compds. [I; R1 = alkyl, (un)substituted aryl; R2, R22 = H, halo, CF3, etc.; R2 and R22 may be together = (un)substituted CH:CHCH:CH; R3, R33 = H, alkyl, or forming a cycloalkyl together with the carbon atom, to which they are attached; R4 = H, alkyl, (un)substituted NH2, etc.; X = CONR5, NR5CO; R5 = H, alkyl, CH2Ph; n = 0-4], useful as antagonists of neurokinin 1 receptor (no data), were prepd. Thus, treating 6-chloronicotinic acid with SOCl2 and MeNH2.HCl followed by reaction of 6-chloro-N-methylnicotinamide with o-tolylmagnesium chloride and 1-methylpiperazine, treatment of 6-(4-methylpiperazin-1-yl)-4-o-tolyl-4,5-dihydropyridine-3-carboxylic acid methylamide with MnO2, and reacting N-methyl-6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide with 3,5-bis(trifluoromethyl)benzyl bromide afforded the nicotinamide II.

IT **342417-03-2P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for prepn. of pyridine derivs.)

RN 342417-03-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-4-(2-methylphenyl)-N-(phenylmethyl)- (9CI)
 (CA INDEX NAME)




IT **290296-68-3P 290297-57-3P 342416-86-8P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (process for prepn. of pyridine derivs.)


RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 342416-86-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-morpholinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:396484 CAPLUS
 DN 135:5620
 TI Preparation of 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(morpholin-4-yl)-4-(o-tolyl)-pyridin-3-yl]-isobutyramide for the treatment of diseases related to the NK-1 receptor
 IN Ballard, Theresa Maria; Higgins, Guy Andrew; Hoffmann, Torsten; Poli, Sonia Maria; Sleight, Andrew
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1103545	A1	20010530	EP 2000-125450	20001121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
GB 2356863	A1	20010606	GB 2000-28566	20001123
NZ 508386	A	20030228	NZ 2000-508386	20001123
DE 10058310	A1	20010531	DE 2000-10058310	20001124
FR 2801590	A1	20010601	FR 2000-15193	20001124
JP 2001151754	A2	20010605	JP 2000-356833	20001124
NO 2000006012	A	20010530	NO 2000-6012	20001128
BR 2000005616	A	20010717	BR 2000-5616	20001128
BG 104992	A	20011130	BG 2000-104992	20001128
ES 2171134	A1	20020816	ES 2000-2839	20001128
CN 1297888	A	20010606	CN 2000-134260	20001129
PRAI EP 1999-123685	A	19991129		

AB The title compd. I which is a potent and selective antagonist at recombinant human neurokinin1 (NK1) receptors expressed in CHO cells, was prepd. (details of multi-step synthesis were given) and formulated. The compd. I showed an affinity (pKi) of 9.0 for the human NK1 receptor over 2 orders of magnitude of selectivity for the NK1 receptor compared to NK2 and NK3 receptors and compared to over 50 other binding sites that have been evaluated.


IT **290296-68-3P 341023-51-6P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(morpholin-4-yl)-4-(o-tolyl)-pyridin-3-yl]-isobutyramide for the treatment of diseases related to the NK-1 receptor)

RN 290296-68-3 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 341023-51-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:607348 CAPLUS
 DN 133:207811
 TI Preparation of N-benzyl-4-tolylnicotinamides and related compounds as neurokinin-1 receptor antagonists.
 IN Boes, Michael; Branca, Quirico; Galley, Guido; Godel, Thierry; Hoffmann, Torsten; Hunkeler, Walter; Schnider, Patrick; Stadler, Heinz
 PA F. Hoffmann-La Roche Ag, Switz.
 SO Ger. Offen., 38 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10008042	A1	20000831	DE 2000-10008042	20000222
	EP 1035115	A1	20000913	EP 2000-102260	20000215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	GB 2347422	A1	20000906	GB 2000-3908	20000218
	NZ 502948	A	20010928	NZ 2000-502948	20000218
	FR 2790473	A1	20000908	FR 2000-2170	20000222
→	US 6297375	B1	20011002	US 2000-507456	20000222
	ZA 2000000894	A	20000824	ZA 2000-894	20000223
	NO 2000000885	A	20000825	NO 2000-885	20000223
	BR 2000000908	A	20000912	BR 2000-908	20000223
	CN 1270959	A	20001025	CN 2000-102401	20000223
	ES 2171109	A1	20020816	ES 2000-418	20000223
	JP 2000247957	A2	20000912	JP 2000-47003	20000224
	BG 104187	A	20001130	BG 2000-104187	20000224
	US 2002091265	A1	20020711	US 2001-901982	20010710
→	US 6479483	B2	20021112		
PRAI	EP 1999-103504	A	19990224		
	EP 1999-123689	A	19991129		
	US 2000-507456	A3	20000222		
OS	MARPAT 133:207811				
AB	Title compds. [I; R = H, alkyl, alkoxy, halo, CF ₃ ; R ₁ = H, halo; RR ₁ = CH:CHCH:CH; R ₂ , R ₂₁ = H, halo, CF ₃ , alkoxy, cyano; R ₂ R ₂₁ = (substituted) CH:CHCH:CH; R ₃ = H, alkyl, cycloalkyl; R ₄ = H, N(R ₅) ₂ , N(R ₅)(CH ₂)nOH, N(R ₅)S(O) ₂ A, N(R ₅)S(O) ₂ Ph, N:CHN(R ₅) ₂ , N(R ₅)C(O)R ₅ , specified cyclic tertiary amine; R ₅ = H, cycloalkyl, benzyl, alkyl; X = C(O)N(R ₅), (CH ₂)mO, (CH ₂)mN(R ₅), N(R ₅)C(O), N(R ₅)(CH ₂)m; n = 0-4; m = 1, 2], were prepd. Thus, 4-o-tolylnicotinic acid (prepn. given) was stirred with SOCl ₂ and cat. DMF in CH ₂ Cl ₂ to give a residue which was refluxed with N-[3,5-bis(trifluoromethyl)benzyl]-N-methylamine and Et ₃ N in PhMe to give 67% N-(3,5-bistrifluoromethylbenzyl)-N-methyl-4-o-tolylnicotinamide. Tested I antagonized NK-1 receptors with pK _i = 8.20-9.54.				
IT	290297-14-2P 290297-18-6P 290297-26-6P 290297-30-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of N-benzyl-4-tolylnicotinamides and related compds. as neurokinin-1 receptor antagonists)				
RN	290297-14-2 CAPLUS				
CN	Benzeneacetamide, N-[6-amino-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX				

NAME)




RN 290297-18-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-26-6 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290297-30-2 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 290296-41-2P 290296-42-3P 290296-43-4P
 290296-44-5P 290296-45-6P 290296-46-7P
 290296-47-8P 290296-48-9P 290296-50-3P
 290296-51-4P 290296-52-5P 290296-53-6P
 290296-54-7P 290296-55-8P 290296-56-9P
 290296-57-0P 290296-58-1P 290296-59-2P
 290296-60-5P 290296-62-7P 290296-63-8P
 290296-65-0P 290296-66-1P 290296-67-2P
 290296-68-3P 290296-69-4P 290296-70-7P
 290296-71-8P 290296-72-9P 290296-73-0P
 290296-74-1P 290296-75-2P 290296-76-3P
 290296-77-4P 290296-78-5P 290296-79-6P
 290296-80-9P 290296-81-0P 290296-82-1P
 290296-83-2P 290296-84-3P 290296-85-4P
 290296-86-5P 290296-87-6P 290296-88-7P
 290296-89-8P 290296-90-1P 290296-91-2P
 290296-92-3P 290296-93-4P 290296-94-5P
 290296-95-6P 290296-96-7P 290296-98-9P
 290296-99-0P 290297-00-6P 290297-01-7P
 290297-02-8P 290297-03-9P 290297-04-0P
 290297-05-1P 290297-06-2P 290297-07-3P
 290297-08-4P 290297-09-5P 290297-10-8P
 290297-11-9P 290297-12-0P 290297-13-1P
 290297-15-3P 290297-16-4P 290297-17-5P
 290297-57-3P 290297-59-5P 290297-60-8P
 290297-61-9P 290297-62-0P 290297-63-1P
 290297-65-3P 290297-66-4P 290298-21-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of N-benzyl-4-tolylnicotinamides and related compds. as neurokinin-1 receptor antagonists)

RN 290296-41-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-42-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 290296-43-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 290296-44-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-45-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 290296-46-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 290296-47-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-ethyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-48-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-cyclopropyl-4-(2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 290296-50-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3,5-difluorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-51-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-52-5 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 290296-53-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 290296-54-7 CAPLUS
 CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-55-8 CAPLUS


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-56-9 CAPLUS


CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-57-0 CAPLUS


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290296-58-1 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 290296-59-2 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-60-5 CAPLUS


CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290296-62-7 CAPLUS


CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290296-63-8 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, hydrochloride (2:3) (9CI) (CA INDEX NAME)



● 3/2 HCl

RN 290296-65-0 CAPLUS


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290296-66-1 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-67-2 CAPLUS


CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]-3-pyridinyl]-3,5-bis(trifluoromethyl)-

(9CI) (CA INDEX NAME)




RN 290296-68-3 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-69-4 CAPLUS


CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(1-piperidinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 290296-70-7 CAPLUS

CN Benzeneacetamide, N-[6-(dimethylamino)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-71-8 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(dimethylamino)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-72-9 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-(1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-73-0 CAPLUS


CN Benzeneacetamide, N-[6-(4-hydroxy-1-piperidinyl)-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-74-1 CAPLUS


CN Benzeneacetamide, N-[6-[(3R)-3-hydroxy-1-pyrrolidinyl]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 290296-75-2 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290296-76-3 CAPLUS

CN Benzeneacetamide, 3,5-dimethoxy-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290296-77-4 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-methyl-N-[4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 290296-78-5 CAPLUS


CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 290296-79-6 CAPLUS

CN 3-Pyridinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-80-9 CAPLUS

CN Pyridine, 3-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 290296-81-0 CAPLUS



CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 290296-82-1 CAPLUS


CN 3-Pyridinemethanamine, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 290296-83-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290296-84-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-85-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290296-86-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-87-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-(acetylmethylamino)-1-pyrrolidinyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-88-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-[methyl[2-(4-morpholinyl)ethyl]amino]-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-89-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-90-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-91-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 290296-92-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290296-94-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-95-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-(cyanomethyl)-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290296-96-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI)
(CA INDEX NAME)




RN 290296-98-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1,2,4-oxadiazol-3-ylmethyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 290296-99-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-[4-[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1-piperazinyl]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-00-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-formyl-1-piperazinyl)-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 290297-01-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-N-[(2-methyl-1-naphthalenyl)methyl]-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-02-8 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-03-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxy-1-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-04-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-05-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-06-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[(2-chloro-5-methoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-07-3 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 290297-08-4 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 290297-09-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-10-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1,4-dimethoxy-2-naphthalenyl)methyl]-N-methyl-4-(2-methylphenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 290297-11-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 290297-12-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-[4-(1H-tetrazol-5-ylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 290297-13-1 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylmethyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-15-3 CAPLUS

CN Benzeneacetamide, N-[6-[[[(dimethylamino)methylene]amino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-16-4 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(methylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-17-5 CAPLUS

CN Benzeneacetamide, N,.alpha.,.alpha.-trimethyl-N-[4-(2-methylphenyl)-6-[(phenylsulfonyl)amino]-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-57-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290297-59-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-6-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 290297-60-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-(2-methylphenyl)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290297-61-9 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 290297-62-0 CAPLUS

CN Benzeneacetamide, N-[4-(4-fluoro-2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-63-1 CAPLUS

CN Benzeneacetamide, N-methyl-N-[4-(2-methylphenyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 290297-65-3 CAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-(4-morpholinyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME).




RN 290297-66-4 CAPLUS

CN 3-Pyridinamine, N-[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 290298-21-4 CAPLUS


CN Benzeneacetamide, N-[6-[(2-hydroxyethyl)methylamino]-4-(2-methylphenyl)-3-pyridinyl]-N,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

IT **290297-47-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of N-benzyl-4-tolylnicotinamides and related compds. as
 neurokinin-1 receptor antagonists)

RN 290297-47-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

IT **290297-31-3P 290297-41-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of N-benzyl-4-tolylnicotinamides and related compds. as
 neurokinin-1 receptor antagonists)


RN 290297-31-3 CAPLUS

CN Cyclopropanecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-3-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 290297-41-5 CAPLUS

CN Carbamic acid, [5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-1-oxopropyl]methylamino]-4-(2-methylphenyl)-2-pyridinyl] (phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:186578 CAPLUS
 DN 108:186578
 TI Preparation of tetrahydropyridine-3-carboxylic acids, esters, and amides
 as therapeutic agents for amnesia and senile dementia
 PA Warner-Lambert Co., USA
 SO Jpn. Kokai Tokkyo Koho, 32 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62192358	A2	19870822	JP 1987-32590	19870217
	JP 08032682	B4	19960329		
	US 4745123	A	19880517	US 1986-830035	19860218
	CA 1285939	A1	19910709	CA 1987-528411	19870128
	EP 235663	A1	19870909	EP 1987-102216	19870217
	EP 235663	B1	19900725		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 54910	E	19900815	AT 1987-102216	19870217
	ES 2029801	T3	19921001	ES 1987-102216	19870217
PRAI	US 1986-830035		19860218		
	EP 1987-102216		19870217		

OS CASREACT 108:186578


AB The title compds. [I; R1 = H, C1-6 alkyl, C1-6 alkenyl, C2-5 alkoxy carbonyl, C4-8 cycloalkyl, (halo, OH, C1-6 alkyl, or C1-4 alkyloxy substituted) PhC1-6alkyl; when R2 = H, R4R6 = bond or when R6 = H, R2R4 = bond; R3 = CO2R7, CONR8R9; R5 = C1-6 alkyl, C1-6 alkenyl, C3-8 cycloalkyl, 2- or 3-thienyl, Ph, halo, NO2, amino, etc.; R7 = C1-6 alkyl, C1-6 alkenyl, C3-8 cycloalkyl, Ph etc.; R8, R9 = H, C1-4 alkyl, or when R8 = H, R9 = C3-8 cycloalkyl, PhCH2O, (substituted) Ph alkyl, or R8R9N = pyrrolidinyl, piperidinyl, morpholino, etc.], useful for treatment of senile dementia and as cholinergic agents, are prepd. from II (R3, R5 = same as I), via III (R1, R3, R5 = same as I; X = halo). II (R3 = CO2H; R5 = Ph) in CH2Cl2 was treated with SO2Cl2 in the presence of Et3N, followed by addn. of Me2NH to give II (R3 = CONMe2; R5 = Ph) which was treated with EtI to afford III (R1 = Et; R3 = CONMe2; R5 = Ph; X = iodo) and redn. of the latter compd. with NaBH4 in EtOH in the presence of 1M HCl gave I (R1 = Et; R2R4 = bond; R3 = CONMe2; R5 = Ph; R6 = H) (IV). IV was converted to its oxalate which showed IC50 of 9 .mu.M at muscarinic receptors, vs. 1.1 .mu.M for arecoline.

IT **114120-64-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and conversion of, to pyridinium salt)

RN 114120-64-8 CAPLUS

CN 3-Pyridinecarboxamide, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **114120-68-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and redn. of, tetrahydropyridine analog from)

RN 114120-68-2 CAPLUS

CN Pyridinium, 4-phenyl-3-[[(phenylmethyl) amino]carbonyl]-1-propyl-, iodide
(9CI) (CA INDEX NAME)



● I⁻

=> d his

(FILE 'HOME' ENTERED AT 08:58:31 ON 29 MAY 2003)

FILE 'REGISTRY' ENTERED AT 08:58:38 ON 29 MAY 2003
 L1 STRUCTURE UPLOADED
 L2 6 S L1 SSS SAM
 L3 278 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 09:04:13 ON 29 MAY 2003
 L4 12 S L3

FILE 'CAOLD' ENTERED AT 09:05:13 ON 29 MAY 2003

=> s 13

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.40	207.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-7.81

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:05:25 ON 29 MAY 2003